- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses New ADA Role; Virtual Scientific Sessions
One advantage of conducting an online scientific conference is that more individuals will gain access to information presented at the meeting, said Robert Gabbay, MD, PhD, the newly appointed chief medical and scientific officer of the American Diabetes Association.
One advantage of conducting an online scientific conference is that more individuals will gain access to information presented at the meeting, said Robert Gabbay, MD, PhD, the newly appointed chief medical and scientific officer of the American Diabetes Association.
Transcript:
As the new chief scientific and medical officer at the American Diabetes Association (ADA), what are your goals for the organization?
It is the most comprehensive organization focused on improving the lives of people with diabetes and serving the professional community around diabetes. I look to continue to foster that wonderful work and really ensure that it has greater impact on all of our constituents.
This is the 80th Scientific Sessions hosted by the ADA, but the first one to be conducted virtually. What are you looking forward to?
I think it's an exciting time. Obviously, we've been challenged by coronavirus disease 2019 (COVID-19) to have to pivot to do this virtually. But what we hope is one of the advantages of doing it virtually, is that we can have more people have access to the amazing information that occurs at this meeting. Some years people can't travel to whatever the location is. Now, we can all do this from the comfort of our office or home. I hope that we have even greater participation as a result. Because we are capturing all of the sessions on video, we have the opportunity then to have this as enduring material that can be distributed again, all over the world.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
